Endocrine Abstracts

Introduction: Continuous Subcutaneous Insulin Infusion (CSII) therapy is an established treatment of Type 1 Diabetes Mellitus (T1DM). NICE recommends a target HbA1c of ≤6.5% to minimise long-term complication risks1. CSII can be considered in patients <12 years and in those with high HbA1c (≥8.5%) on multiple daily insulin injections, despite a high level of care1. The aim of this audit is to review diabetes control over time in T1DM patie...

Background: During 2017–2018 the diabetic team at our Foundation Trust participated in the RCPCH diabetes quality improvement collaborative to support work in reducing the mean HbA1c of our patient cohort. It is widely acknowledged that a consistent approach is vital in working towards HbA1c targets. One area of focus of our quality improvement work was to standardise the management of hypoglycaemia. As a team we decided to follow the BSPED hypoglycaemia guideline (2016) ...